Prasad: China produces semaglutide far more efficiently via biologics than India can
G. V. Prasad · Two Pharma Giants Who'd Never Met | Mankind & Dr. Reddy's | WTF is Pharma? · Nikhil Kamath · Jun 17, 2026 · at 2:28:40
Dr. Reddy's Laboratories co-chairman G.V. Prasad compares Chinese and Indian manufacturing methods for producing GLP-1 weight-loss and diabetes drugs like semaglutide.
0:00 / 0:17exact quote · 18.0s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“The Chinese are much better at biological processors, and the GLP-I they make, the semaglutide they make is from a biologic route. So they're able to scale it much, much better than Indians. Indian companies are largely in synthesis, which is an inefficient way of making semaglutide.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from G. V. Prasad
Prasad: Dr. Reddy's clinical trials found no significant medical efficacy in turmeric
“We've done trials with turmeric, we didn't see significant.”
Prasad: Dr. Reddy's found Chinese suppliers more reliable than Indian peers during COVID
“In COVID time, I'm telling you this, in COVID time, we had more reliable supplies from China than from Indian companies.”
Prasad: E-pharmacies are highly capital intensive and Tata 1mg remains unprofitable
“Online business can happen, but then you require a huge amount of capital. It's not a twenty-five-year-old's job. Tata MG, One MG is still not profitable.”
Prasad: Scaling hospital chains is difficult because it is fundamentally real estate
“I think it's a very difficult game to scale because it's a real estate play at the end of the day.”
Prasad: US 100% tariffs on non-US innovative drugs threaten Indian CDMOs
“No, if you're selling it to the US, and it's an innovative drug, not a generic drug, and it's not manufactured in the US, it's manufactured in India, there is a likelihood of a hundred percent tariff. So this affects our CDMO industry, the contract development…”